We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00298688
Recruitment Status : Completed
First Posted : March 3, 2006
Last Update Posted : June 12, 2008
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib

Condition or disease Intervention/treatment Phase
Small Cell Lung Cancer Drug: Gefitinib Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer
Study Start Date : September 2004
Study Completion Date : March 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Gefitinib
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. To determine the disease control rate in these patients

Secondary Outcome Measures :
  1. To determine the objective response rate at trail closure in these patients
  2. To determine the time to progression-or-death in these patients
  3. To determine overall survival in these patients

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provision of written informed consent
  • Histologically confirmed, relapsed or refractory SCLCr
  • Aged 18 or over and a life expectancy of more than 2 months

Exclusion Criteria:

  • Any evidence of clinically active interstitial lung disease
  • Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00298688

Research Site
Copenhagen, Denmark
Research Site
Herlev, Denmark
United Kingdom
Research Site
Manchester, United Kingdom
Sponsors and Collaborators
Study Director: AstraZeneca Iressa Medical Science Director, MD AstraZeneca
More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00298688     History of Changes
Other Study ID Numbers: 1839IL/0559
First Posted: March 3, 2006    Key Record Dates
Last Update Posted: June 12, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action